Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

NCT07046182 is registered in ClinicalTrials.gov with Zhengzhou University as lead sponsor.

NCT NCT07046182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07046182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
Lead sponsor
Zhengzhou University
Phase
Phase 4
Overall status
Active, not recruiting
Start date
October 21, 2023
Completion date
May 26, 2028
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma (aitl)